Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pharmacoepidemiology | 18 | 2024 | 350 | 4.310 |
Why?
|
Research Design | 22 | 2024 | 6180 | 2.490 |
Why?
|
Databases, Factual | 18 | 2024 | 8022 | 2.080 |
Why?
|
Propensity Score | 12 | 2024 | 1926 | 1.960 |
Why?
|
Product Surveillance, Postmarketing | 4 | 2021 | 450 | 1.430 |
Why?
|
Data Mining | 7 | 2023 | 553 | 1.410 |
Why?
|
Advisory Committees | 4 | 2022 | 788 | 1.360 |
Why?
|
Warfarin | 7 | 2023 | 1518 | 1.220 |
Why?
|
Immunization Schedule | 2 | 2020 | 224 | 1.210 |
Why?
|
Anticoagulants | 11 | 2024 | 4897 | 1.150 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 10343 | 1.100 |
Why?
|
Delivery of Health Care | 10 | 2024 | 5325 | 1.050 |
Why?
|
Electronic Health Records | 12 | 2024 | 4775 | 0.990 |
Why?
|
Research Report | 3 | 2022 | 370 | 0.930 |
Why?
|
Factor XI | 1 | 2024 | 34 | 0.920 |
Why?
|
Bronchodilator Agents | 2 | 2024 | 506 | 0.880 |
Why?
|
Scientific Misconduct | 1 | 2024 | 74 | 0.880 |
Why?
|
Information Storage and Retrieval | 2 | 2019 | 822 | 0.870 |
Why?
|
Atrial Fibrillation | 9 | 2023 | 5209 | 0.850 |
Why?
|
Cross-Over Studies | 7 | 2021 | 2061 | 0.850 |
Why?
|
Adverse Drug Reaction Reporting Systems | 5 | 2023 | 488 | 0.770 |
Why?
|
Evidence-Based Medicine | 5 | 2024 | 3696 | 0.760 |
Why?
|
Haemophilus Vaccines | 1 | 2020 | 71 | 0.720 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2020 | 37 | 0.700 |
Why?
|
Drug Evaluation | 1 | 2021 | 641 | 0.690 |
Why?
|
Thromboembolism | 4 | 2024 | 1016 | 0.690 |
Why?
|
Neonatal Abstinence Syndrome | 1 | 2021 | 108 | 0.680 |
Why?
|
Medical Informatics Applications | 1 | 2021 | 178 | 0.650 |
Why?
|
Workflow | 1 | 2024 | 852 | 0.640 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2024 | 3226 | 0.630 |
Why?
|
Valproic Acid | 1 | 2021 | 441 | 0.620 |
Why?
|
Abnormalities, Drug-Induced | 1 | 2021 | 338 | 0.620 |
Why?
|
Wet Macular Degeneration | 1 | 2020 | 162 | 0.610 |
Why?
|
Data Collection | 5 | 2022 | 3315 | 0.610 |
Why?
|
Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2018 | 52 | 0.600 |
Why?
|
Drugs, Generic | 2 | 2020 | 448 | 0.590 |
Why?
|
Measles-Mumps-Rubella Vaccine | 1 | 2018 | 72 | 0.580 |
Why?
|
Technology | 1 | 2019 | 291 | 0.560 |
Why?
|
Choroidal Neovascularization | 1 | 2020 | 357 | 0.560 |
Why?
|
Pneumococcal Vaccines | 1 | 2020 | 397 | 0.550 |
Why?
|
Hemorrhage | 8 | 2023 | 3599 | 0.530 |
Why?
|
Natural Language Processing | 3 | 2019 | 1135 | 0.530 |
Why?
|
Calcium Channel Blockers | 1 | 2019 | 694 | 0.520 |
Why?
|
Peer Review | 1 | 2017 | 218 | 0.500 |
Why?
|
Epidemiologic Research Design | 2 | 2018 | 368 | 0.490 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2020 | 1347 | 0.490 |
Why?
|
Reproducibility of Results | 12 | 2024 | 20080 | 0.490 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 2 | 2018 | 1523 | 0.480 |
Why?
|
Data Interpretation, Statistical | 6 | 2021 | 2696 | 0.470 |
Why?
|
Medical Records | 1 | 2019 | 1407 | 0.450 |
Why?
|
Software | 4 | 2024 | 4419 | 0.440 |
Why?
|
Research | 2 | 2020 | 1974 | 0.420 |
Why?
|
Humans | 85 | 2024 | 760613 | 0.410 |
Why?
|
Glaucoma, Open-Angle | 1 | 2019 | 734 | 0.410 |
Why?
|
Tetrazoles | 1 | 2018 | 905 | 0.410 |
Why?
|
Decision Making | 4 | 2020 | 3925 | 0.400 |
Why?
|
Antihypertensive Agents | 2 | 2019 | 2061 | 0.400 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2018 | 1031 | 0.390 |
Why?
|
Drug Combinations | 3 | 2024 | 2025 | 0.390 |
Why?
|
Androstadienes | 2 | 2024 | 348 | 0.390 |
Why?
|
Pneumonia | 1 | 2023 | 2131 | 0.390 |
Why?
|
Drug Approval | 1 | 2018 | 816 | 0.380 |
Why?
|
Control Groups | 1 | 2011 | 104 | 0.380 |
Why?
|
Administration, Inhalation | 2 | 2024 | 1156 | 0.360 |
Why?
|
Heart Failure | 7 | 2024 | 11848 | 0.360 |
Why?
|
Analgesics, Opioid | 3 | 2021 | 3763 | 0.330 |
Why?
|
Cohort Studies | 15 | 2024 | 41337 | 0.330 |
Why?
|
Longitudinal Studies | 3 | 2021 | 14494 | 0.320 |
Why?
|
Algorithms | 6 | 2024 | 13982 | 0.310 |
Why?
|
Models, Theoretical | 1 | 2020 | 3562 | 0.310 |
Why?
|
Case-Control Studies | 8 | 2021 | 22052 | 0.310 |
Why?
|
Seizures | 2 | 2018 | 2917 | 0.300 |
Why?
|
Medicare | 10 | 2023 | 6785 | 0.280 |
Why?
|
United States | 24 | 2023 | 72448 | 0.280 |
Why?
|
Stroke | 7 | 2023 | 9952 | 0.270 |
Why?
|
Vaccination | 2 | 2019 | 3359 | 0.270 |
Why?
|
Models, Statistical | 4 | 2024 | 5075 | 0.270 |
Why?
|
Drug Substitution | 2 | 2020 | 296 | 0.260 |
Why?
|
Guidelines as Topic | 4 | 2024 | 1392 | 0.260 |
Why?
|
Sentinel Surveillance | 2 | 2018 | 293 | 0.260 |
Why?
|
Disease Progression | 2 | 2020 | 13505 | 0.260 |
Why?
|
Medicaid | 4 | 2023 | 2815 | 0.240 |
Why?
|
Models, Biological | 2 | 2018 | 9468 | 0.240 |
Why?
|
Computer Simulation | 7 | 2024 | 6218 | 0.240 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 3985 | 0.240 |
Why?
|
Asthma | 1 | 2023 | 6172 | 0.240 |
Why?
|
Aged | 29 | 2024 | 169143 | 0.230 |
Why?
|
Influenza Vaccines | 2 | 2023 | 766 | 0.230 |
Why?
|
Famotidine | 1 | 2022 | 17 | 0.210 |
Why?
|
Brain Ischemia | 2 | 2018 | 3127 | 0.210 |
Why?
|
Antipsychotic Agents | 2 | 2014 | 3061 | 0.200 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5890 | 0.190 |
Why?
|
Time Factors | 11 | 2024 | 40139 | 0.190 |
Why?
|
Physicians | 1 | 2019 | 4591 | 0.190 |
Why?
|
Economics, Pharmaceutical | 2 | 2020 | 88 | 0.180 |
Why?
|
Terminology as Topic | 2 | 2019 | 1535 | 0.180 |
Why?
|
Teratogens | 1 | 2021 | 117 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5251 | 0.180 |
Why?
|
Spironolactone | 1 | 2024 | 411 | 0.180 |
Why?
|
Prognosis | 4 | 2024 | 29661 | 0.170 |
Why?
|
Drug Monitoring | 2 | 2018 | 965 | 0.170 |
Why?
|
Embolism | 1 | 2023 | 408 | 0.170 |
Why?
|
Bacterial Capsules | 1 | 2020 | 242 | 0.170 |
Why?
|
Utah | 1 | 2019 | 131 | 0.170 |
Why?
|
Particulate Matter | 1 | 2011 | 2559 | 0.170 |
Why?
|
Aged, 80 and over | 12 | 2020 | 58980 | 0.160 |
Why?
|
Adrenergic Antagonists | 1 | 2018 | 26 | 0.160 |
Why?
|
Risk Assessment | 8 | 2024 | 24102 | 0.150 |
Why?
|
Drug Repositioning | 1 | 2020 | 232 | 0.150 |
Why?
|
Insurance Claim Review | 2 | 2020 | 738 | 0.150 |
Why?
|
Sulfonylurea Compounds | 1 | 2019 | 221 | 0.150 |
Why?
|
Glipizide | 1 | 2017 | 48 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 140 | 0.150 |
Why?
|
Perioperative Care | 2 | 2015 | 1037 | 0.150 |
Why?
|
Hypoglycemic Agents | 3 | 2021 | 3149 | 0.150 |
Why?
|
Checklist | 1 | 2024 | 827 | 0.150 |
Why?
|
Air Pollution | 1 | 2011 | 2317 | 0.140 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 163 | 0.140 |
Why?
|
Hospitalization | 6 | 2024 | 10789 | 0.140 |
Why?
|
Female | 25 | 2024 | 391246 | 0.140 |
Why?
|
Glyburide | 1 | 2017 | 114 | 0.140 |
Why?
|
Stroke Volume | 3 | 2024 | 5523 | 0.140 |
Why?
|
Prescription Drugs | 2 | 2014 | 630 | 0.140 |
Why?
|
Male | 25 | 2024 | 359718 | 0.140 |
Why?
|
Angioedema | 1 | 2018 | 192 | 0.140 |
Why?
|
Vitamin K | 2 | 2020 | 321 | 0.140 |
Why?
|
Environmental Exposure | 1 | 2011 | 4412 | 0.130 |
Why?
|
Information Dissemination | 1 | 2024 | 1131 | 0.130 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1257 | 0.130 |
Why?
|
Trust | 1 | 2020 | 532 | 0.130 |
Why?
|
Proportional Hazards Models | 4 | 2020 | 12531 | 0.120 |
Why?
|
Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 334 | 0.120 |
Why?
|
Statistics as Topic | 2 | 2018 | 2362 | 0.120 |
Why?
|
Antithrombins | 1 | 2018 | 313 | 0.120 |
Why?
|
Logistic Models | 6 | 2020 | 13312 | 0.120 |
Why?
|
Ketolides | 1 | 2014 | 12 | 0.120 |
Why?
|
Odds Ratio | 4 | 2020 | 9716 | 0.120 |
Why?
|
Risk | 2 | 2020 | 9632 | 0.120 |
Why?
|
Lung Neoplasms | 1 | 2019 | 13262 | 0.120 |
Why?
|
Evidence-Based Practice | 1 | 2018 | 496 | 0.110 |
Why?
|
Biphenyl Compounds | 1 | 2018 | 992 | 0.110 |
Why?
|
Postoperative Period | 1 | 2018 | 1818 | 0.110 |
Why?
|
United States Food and Drug Administration | 2 | 2018 | 1677 | 0.110 |
Why?
|
Isoxazoles | 1 | 2014 | 230 | 0.100 |
Why?
|
International Normalized Ratio | 1 | 2014 | 387 | 0.100 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2014 | 321 | 0.100 |
Why?
|
Marketing | 1 | 2014 | 220 | 0.100 |
Why?
|
Middle Aged | 14 | 2024 | 220359 | 0.100 |
Why?
|
Comparative Effectiveness Research | 1 | 2017 | 718 | 0.100 |
Why?
|
Pennsylvania | 1 | 2013 | 615 | 0.100 |
Why?
|
Metformin | 1 | 2019 | 912 | 0.100 |
Why?
|
Automation | 1 | 2014 | 580 | 0.100 |
Why?
|
Adult | 12 | 2024 | 220007 | 0.090 |
Why?
|
Mathematical Computing | 1 | 2011 | 143 | 0.090 |
Why?
|
Secondary Prevention | 1 | 2018 | 1548 | 0.090 |
Why?
|
Clostridium Infections | 1 | 2018 | 557 | 0.090 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2021 | 12289 | 0.090 |
Why?
|
Quinolones | 1 | 2014 | 377 | 0.090 |
Why?
|
Treatment Outcome | 8 | 2024 | 64981 | 0.090 |
Why?
|
Medical Oncology | 1 | 2022 | 2313 | 0.090 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.090 |
Why?
|
Registries | 2 | 2024 | 8458 | 0.090 |
Why?
|
Pregnancy Outcome | 1 | 2021 | 2907 | 0.090 |
Why?
|
Hypoglycemia | 1 | 2017 | 888 | 0.090 |
Why?
|
Primary Prevention | 1 | 2018 | 1207 | 0.090 |
Why?
|
Age Factors | 3 | 2018 | 18413 | 0.090 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2015 | 1259 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2001 | 0.080 |
Why?
|
Drug Utilization | 1 | 2015 | 1195 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6544 | 0.080 |
Why?
|
Incidence | 5 | 2019 | 21391 | 0.080 |
Why?
|
Disease-Free Survival | 1 | 2019 | 6831 | 0.080 |
Why?
|
Epidemiologic Methods | 1 | 2013 | 1343 | 0.080 |
Why?
|
Drug Therapy, Combination | 1 | 2018 | 6498 | 0.080 |
Why?
|
Influenza, Human | 1 | 2019 | 1528 | 0.070 |
Why?
|
Anti-Bacterial Agents | 2 | 2018 | 7408 | 0.070 |
Why?
|
Risk Factors | 8 | 2023 | 74333 | 0.070 |
Why?
|
Infant | 2 | 2020 | 36053 | 0.070 |
Why?
|
Antidepressive Agents | 1 | 2019 | 2890 | 0.070 |
Why?
|
United States Department of Veterans Affairs | 1 | 2011 | 919 | 0.070 |
Why?
|
Patient Selection | 1 | 2018 | 4279 | 0.070 |
Why?
|
Survival Analysis | 1 | 2019 | 10185 | 0.070 |
Why?
|
Ventricular Function, Left | 1 | 2018 | 3880 | 0.060 |
Why?
|
Recurrence | 1 | 2018 | 8483 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1977 | 0.060 |
Why?
|
Denmark | 2 | 2018 | 760 | 0.060 |
Why?
|
Piperazines | 1 | 2014 | 2525 | 0.060 |
Why?
|
Adolescent | 6 | 2022 | 87809 | 0.060 |
Why?
|
Child, Preschool | 3 | 2020 | 42056 | 0.050 |
Why?
|
Calibration | 1 | 2024 | 816 | 0.050 |
Why?
|
Omeprazole | 1 | 2022 | 112 | 0.050 |
Why?
|
Cardiovascular Diseases | 3 | 2015 | 15760 | 0.050 |
Why?
|
Epilepsy | 1 | 2016 | 3267 | 0.050 |
Why?
|
Infant, Newborn | 1 | 2021 | 26179 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2022 | 80345 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2015 | 3332 | 0.040 |
Why?
|
Pregnancy | 1 | 2021 | 29746 | 0.040 |
Why?
|
Reference Standards | 1 | 2022 | 1004 | 0.040 |
Why?
|
Vaccines, Inactivated | 1 | 2019 | 180 | 0.040 |
Why?
|
Taiwan | 1 | 2019 | 505 | 0.040 |
Why?
|
Orthomyxoviridae | 1 | 2019 | 148 | 0.040 |
Why?
|
Research Personnel | 1 | 2022 | 582 | 0.040 |
Why?
|
Veterans | 1 | 2011 | 2642 | 0.040 |
Why?
|
Causality | 1 | 2024 | 1242 | 0.040 |
Why?
|
Child | 3 | 2020 | 79799 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2018 | 288 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2022 | 551 | 0.040 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2019 | 149 | 0.030 |
Why?
|
Societies, Scientific | 1 | 2017 | 221 | 0.030 |
Why?
|
Emergency Service, Hospital | 2 | 2017 | 7818 | 0.030 |
Why?
|
Community Health Planning | 1 | 2016 | 166 | 0.030 |
Why?
|
Insurance, Health | 2 | 2018 | 2501 | 0.030 |
Why?
|
Phenprocoumon | 1 | 2014 | 20 | 0.030 |
Why?
|
Codeine | 1 | 2014 | 51 | 0.030 |
Why?
|
Tramadol | 1 | 2014 | 60 | 0.030 |
Why?
|
Program Development | 1 | 2020 | 1297 | 0.030 |
Why?
|
Young Adult | 5 | 2019 | 58748 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2024 | 15840 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2018 | 894 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2015 | 15679 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3113 | 0.030 |
Why?
|
Insurance Coverage | 1 | 2023 | 1939 | 0.020 |
Why?
|
Internationality | 1 | 2017 | 1004 | 0.020 |
Why?
|
Massachusetts | 1 | 2024 | 8803 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4035 | 0.020 |
Why?
|
Age Distribution | 1 | 2016 | 2893 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2018 | 2326 | 0.020 |
Why?
|
Drug Interactions | 1 | 2014 | 1428 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54306 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2018 | 2754 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4899 | 0.020 |
Why?
|
Anticonvulsants | 1 | 2016 | 1879 | 0.020 |
Why?
|
Comorbidity | 1 | 2020 | 10553 | 0.020 |
Why?
|
Predictive Value of Tests | 1 | 2018 | 15286 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10546 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2015 | 39262 | 0.010 |
Why?
|